Intermediateapplied biology
Antibiotics and the Resistance Crisis
Learning objectives
- Identify the structural differences between bacterial and human cells that antibiotics exploit.
- Describe the major antibiotic target classes: cell wall, protein synthesis, and DNA replication.
- Explain how mutation and selection produce resistant bacterial populations.
- Describe horizontal gene transfer and its role in spreading resistance genes.
- Evaluate strategies to slow resistance, from stewardship to phage therapy.
Bacteria: A Quick Refresher
Bacteria are prokaryotes: single cells without a nucleus, with DNA in a circular chromosome floating in the cytoplasm. Most have a rigid cell wall built from peptidoglycan, a mesh-like polymer human cells completely lack. Their ribosomes, the protein-building machines, are the smaller 70S type, while human ribosomes are 80S. They replicate their DNA with bacterial enzymes such as DNA gyrase. These differences are the foundation of antibiotic therapy: a drug that attacks peptidoglycan synthesis or the 70S ribosome harms bacteria while sparing human cells. Selectivity is never perfect, which is why antibiotics have side effects, but the structural gap between prokaryotic and eukaryotic cells is what makes the drugs possible at all.
How Antibiotics Attack Bacteria
Antibiotics are grouped by the bacterial machinery they sabotage. Beta-lactams, including penicillins and cephalosporins, block the enzymes that cross-link peptidoglycan, so growing bacteria assemble fatally weak walls and burst from their own internal pressure. A second family, including tetracyclines, macrolides, and aminoglycosides, binds the bacterial 70S ribosome and jams protein synthesis, starving the cell of the enzymes it needs to live. Fluoroquinolones inhibit DNA gyrase and topoisomerase, tangling bacterial DNA so replication and transcription grind to a halt. Some antibiotics are bactericidal, killing outright, while others are bacteriostatic, merely halting growth so the immune system can finish the job. Because each class hits a specific target, a bacterium needs a dedicated countermeasure against each one, which is why combination therapy and narrow-spectrum prescribing can slow resistance.
How Resistance Evolves
Resistance arises through the same engine as all evolution: mutation plus selection. In any large bacterial population, a few cells carry random mutations that slightly reduce a drug's effectiveness. When antibiotics kill the susceptible majority, these survivors multiply into a resistant population; the drug itself provides the selection pressure. Bacteria also deploy dedicated countermeasures: beta-lactamase enzymes that chew up penicillins, efflux pumps that flush drugs out of the cell, modifications to the drug's target site, and porin changes that reduce drug entry. Each mechanism is encoded by genes, and once those genes exist in a population, selection preserves them. This is why resistance is inevitable wherever antibiotics are used, and why the goal is to slow it, not to defeat evolution permanently.
Antibiotics do not create resistant mutants; they kill susceptible cells, leaving pre-existing resistant variants to dominate. Every unnecessary dose strengthens this selection.
Resistance Spreads: Horizontal Gene Transfer
Bacteria do not rely on vertical inheritance alone. Through horizontal gene transfer, they swap DNA directly: conjugation passes plasmids, small DNA rings, through a bridge between cells; transformation picks up free DNA from the environment; transduction delivers DNA via bacterial viruses. Resistance genes frequently ride on plasmids carrying multiple resistance cassettes, so one transfer event can confer resistance to several drug classes at once, and it can cross species boundaries. This is how methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacterales spread globally. Hospitals, farms, and wastewater become mixing zones where diverse bacteria exchange these genetic tools, turning local resistance into a worldwide problem. Hospitals amplify the problem because antibiotics, vulnerable patients, and diverse bacteria coincide there, which is why infection-control practices like hand hygiene and patient isolation matter as much as prescribing discipline in slowing spread.
A single conjugative plasmid can carry resistance to beta-lactams, aminoglycosides, and sulfonamides simultaneously, creating multidrug-resistant strains in one transfer.
Fighting Back: Stewardship and New Science
Because resistance is driven by selection, the first defense is using antibiotics wisely, an approach called stewardship: prescribing them only for bacterial infections, choosing narrow-spectrum drugs when possible, and using rapid diagnostics to avoid guesswork. Agriculture matters too, since large volumes of antibiotics used in livestock create selection pressure that reaches humans through food and the environment. On the innovation side, researchers are developing new drug classes, but the economics are difficult because novel antibiotics are deliberately used sparingly. Alternatives in the pipeline include bacteriophage therapy, which uses viruses that infect only bacteria, antimicrobial peptides, and vaccines against bacterial pathogens. None is a silver bullet; the realistic future combines careful use of existing drugs with a diversified toolkit.
Health agencies advise taking antibiotics exactly as prescribed and never sharing them. This article is educational and not personal medical advice.
Key points
- Antibiotics target structures unique to bacteria: peptidoglycan walls, 70S ribosomes, and bacterial DNA enzymes.
- Resistance evolves by mutation plus selection; antibiotics kill susceptible cells and leave resistant ones.
- Bacteria counterattack with degrading enzymes, efflux pumps, and target modifications.
- Horizontal gene transfer via plasmids spreads resistance genes across species.
- Stewardship, diagnostics, and new approaches like phage therapy aim to slow, not stop, resistance.
Common misconceptions
✓ Truth: Colds and flu are caused by viruses, which lack the bacterial targets antibiotics attack. Antibiotics do nothing against viruses, and using them for viral illness only adds selection pressure for resistance.
✓ Truth: Your body does not change; the bacteria do. Resistant infections are harder to treat no matter whose body they are in, because the bacterial population itself carries resistance genes.
✓ Truth: Stopping early can leave the hardiest bacteria alive to rebound. Public-health guidance is to complete the course exactly as prescribed, so the full susceptible population is eliminated.
Frequently asked questions
What is a superbug?
A superbug is a bacterial strain resistant to multiple antibiotics, such as MRSA or carbapenem-resistant Enterobacterales. The term describes the bacterium's drug resistance, not its virulence; many superbugs are ordinary bacteria that have collected resistance genes and become very hard to treat.
Why can't scientists just invent new antibiotics?
They can, but it is slow and expensive: a new drug takes a decade or more and over a billion dollars to develop. Worse, new antibiotics are held in reserve and used sparingly to delay resistance, which makes them poor commercial investments. This broken market is a major reason the pipeline is thin.
Do antibacterial soaps and cleaners contribute to resistance?
Some can. Widespread use of biocides like triclosan selects for bacteria with efflux pumps and other defenses that can also reduce antibiotic susceptibility. Health agencies now advise that plain soap and water are sufficient for routine handwashing.
Can resistance ever be reversed?
Sometimes, partially. Resistance genes carry a fitness cost, so if a drug is withdrawn, susceptible strains can outcompete resistant ones over time. But compensatory mutations often erase that cost, and resistance genes persist in the environment, so reversal is slow and unreliable.